Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma
Authors
Keywords
Paclitaxel, Maximum Tolerate Dose, Dose Cohort, Granulocyte Colony Stimulate Factor Treatment, Metastatic Nasopharyngeal Carcinoma
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-07-13
DOI
10.1186/s12885-016-2517-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nab-paclitaxel: A flattering facelift
- (2014) A. Viúdez et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma
- (2014) Timothy T.C. Yip et al. ORAL ONCOLOGY
- SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients
- (2014) Neil Desai et al. Translational Oncology
- Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinoma
- (2014) Susanna Hilda Hutajulu et al. Therapeutics and Clinical Risk Management
- SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma 2013
- (2013) R. Mesía et al. Clinical & Translational Oncology
- Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma
- (2013) Cheng-Lung Hsu et al. ORAL ONCOLOGY
- Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma
- (2012) Cui Chen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy
- (2012) Ross A Soo et al. Future Oncology
- Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma
- (2012) Ying Jin et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- (2012) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis
- (2012) Hai-Yun Wang et al. Journal of Translational Medicine
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
- (2011) M. D. Galsky et al. ANNALS OF ONCOLOGY
- Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy
- (2011) Xin An et al. CANCER
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer
- (2011) Huanjie Shao et al. Journal of Thoracic Oncology
- The prevalence and prevention of nasopharyngeal carcinoma in China
- (2011) Su-Mei Cao et al. Chinese Journal of Cancer
- Different Clinical Significance of Pre- and Post-treatment Plasma Epstein–Barr Virus DNA Load in Nasopharyngeal Carcinoma Treated with Radiotherapy
- (2010) Xue Hou et al. CLINICAL ONCOLOGY
- Treatment for metastatic nasopharyngeal carcinoma
- (2010) Y. Bensouda et al. European Annals of Otorhinolaryngology-Head and Neck Diseases
- Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma
- (2008) Swan Swan Leong et al. CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now